Saturday 17 October 2026 Export PDLI’s income statement to Excel — free account

PDL BioPharma, Inc.

Follow PDLI

Alert me

Market cap: —
P/E: 0.0×
Fwd P/E: −4.5×
Dividend yield: —
F-score: 3/9
Altman Z: n/a
Beneish M: 16.32
Dividend safety: 45/100

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 32.99%

Capital & Financial Ratios $m

Market Cap —

Revenue 51.81

Net Income (137.17)

Free Cash Flow (6.85)

Net Debt (91.94)

Current Ratio 13.68

Debt/Equity 0.03

P/E ratio 0.00

Fwd P/E (4.45)

P/S ratio 5.53

P/B ratio 0.68

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth (72.06%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2017	2018	2019	Q'20
Cash	532	395	193	105
Receivables	31	22	14	6
Inventory	9	19	40	13
Other	—	—	—	289
	640	517	314	496

	2017	2018	2019	Q'20
Payables	20	13	17	4
ST’ Debt	—	—	—	—
Other	—	—	—	18
	193	52	46	36

Compound Annual Growth %

	10y	5y	3y
Sales	(16.14%)	(37.65%)	(39.26%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	5.20%	(7.74%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	6	5	—	—	—
’19	7	7	44	—	55
’18	39	47	68	45	198
’17	45	144	63	68	320

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(20)	—	—	—
’19	(2)	23	(34)	(19)	(32)
’18	(14)	(6)	8	(2)	(13)
’17	46	16	(4)	(17)	41

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(20)	—	—	—
’19	(2)	21	29	2	49
’18	(15)	29	7	19	40
’17	67	42	22	15	147

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.26)	(0.43)	—	—	—
’19	0.05	(0.04)	(0.16)	(0.48)	(0.59)
’18	0.01	(0.76)	0.18	0.11	(0.47)
’17	0.04	0.39	0.14	0.15	0.71

Fiscal quarters ending in the months shown.

Group	Line	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021e
Price, $
Price, $	Low	—	—	—	—	—	—	—	—	—	—	Analyst estimates 2021–2023 Powerpack
	High	—	—	—	—	—	—	—	—	—	—
People
People	Employees	—	—	—	—	—	11	87	20	75	11
	Revenue/emp, $m	—	—	—	—	—	22.21	3.68	9.91	0.73	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	244	320	198	55	—
	Gross margin, %	—	—	—	—	—	98.34	90.46	75.54	2.08	—
	EBT	—	—	—	—	—	109	185	(56)	(74)	—
	EBT margin, %	—	—	—	—	—	44.77	57.65	(28.23)	(134.67)	—
	Net income	—	—	—	—	—	64	111	(69)	(71)	0
	Depreciation	—	—	—	—	—	22	38	27	17	—
Per share, $
Per share, $	Revenue	—	—	—	—	—	1.49	2.06	1.36	0.46	—
	Earnings	—	—	—	—	—	0.39	0.71	(0.47)	(0.59)	—
	Cash flow	—	—	—	—	—	0.62	0.26	(0.09)	(0.27)	—
	Capex	—	—	—	—	—	0.08	0.68	0.37	0.69	—
	Free cash flow	—	—	—	—	—	0.70	0.94	0.27	0.42	—
	Book value	—	—	—	—	—	4.61	5.44	5.01	5.00	—
	Shares, m	—	—	—	—	—	164	155	146	119	—
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	5.72	3.99	0.00	0.00	—
	P/S	—	—	—	—	—	1.50	1.39	2.13	7.04	—
	P/B	—	—	—	—	—	0.48	0.53	0.58	0.65	—
	EV/Sales	—	—	—	—	—	1.46	0.10	0.77	4.45	—
	EV/FCF	—	—	—	—	—	3.10	0.21	2.09	3.47	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	102	41	(13)	(32)	—
	Capex	—	—	—	—	—	13	106	53	82	—
	Free cash flow	—	—	—	—	—	115	147	40	49	—
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	268	447	465	268	—
	Total debt	—	—	—	—	—	232	117	125	27	—
	Net debt	—	—	—	—	—	(10)	(415)	(270)	(166)	—
	Shareholders’ equity	—	—	—	—	—	755	846	730	593	—
Returns, %
Returns, %	ROA	—	—	—	—	—	5.71	9.01	(6.24)	(8.38)	0.00
	ROIC	—	—	—	—	—	10.85	28.09	(6.88)	(14.61)	—
	ROE	—	—	—	—	—	8.76	13.83	(8.74)	(10.64)	—

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2019 · latest quarter Jun 2020 · fundamentals updated 1 Oct 2026

Charts ten years each

No peers yet.